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A B s T r A C T
Pylephlebitis or septic thrombophlebitis of the portal vein 
is a rare entity with a high mortality rate. it is often a 
complication of intra-abdominal infection most commonly 
caused by diverticulitis and appendicitis. diagnosis is often 
delayed since clinical signs and symptoms are nonspecific. 
Pylephlebitis should be considered in patients with sepsis 
due to gut-associated organisms without a clear focus of 
infection.
We describe a patient with metastastatic colon carcinoma 
treated with chemotherapy and bevacizumab who was 
diagnosed with pylephlebitis after a duodenal ulcer and 
responded well to antibiotic treatment.
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i N T r o d U C T i o N
Pylephlebitis or septic thrombophlebitis of the portal 
vein is a serious condition with significant morbidity and 
mortality. It is a rare complication of intra-abdominal 
infection that occurs in the region drained by the portal 
venous system.1,2 It has only been described once before in 
relation to a duodenal ulcer.3 The diagnosis of pylephlebitis 
requires the demonstration of a portal vein thrombosis 
usually accompanied by bacteraemia in a febrile patient.1 
Diagnosis is often difficult since no specific clinical signs, 
symptoms and laboratory parameters are involved. This 
may lead to a delay in treatment.2
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We made a diagnosis of pylephlebitis in a patient treated 
for metastastatic colon carcinoma, which occurred after a 
bleeding duodenal ulcer. 
C A s E  r E P o r T
A 68-year-old male developed recurrence of liver 
metastases from colon carcinoma after hemicolectomy 
and a hemihepatectomy. Two months after systemic 
treatment was initiated with capecitabine, oxaliplatin and 
bevacizumab (CAIRO-2 Trial of the Dutch Colorectal 
Cancer Group, DCCG) he developed upper gastrointestinal 
bleeding due to a severe duodenal ulcer. There was no 
history of use of nonsteroidal anti-inflammatory drugs. 
Treatment with pantoprazol was started. Chemotherapy 
and bevacizumab were temporarily discontinued. One 
week later this patient presented with general malaise, 
fever, chills and abdominal pain in the upper right 
quadrant. There were no complaints of nausea or vomiting. 
At physical examination his blood pressure was 100/65 
mmHg, heart rate was 110 beats/min. and his temperature 
was 39.4°C. His abdomen was tender upon palpation 
without signs of peritoneal involvement. Hepatomegaly 
was noted but appeared to be unchanged. Initial laboratory 
findings revealed a white blood cell count of 6.3 x 109/l 
(normal 3.5 to 11.0 x 109/l), haemoglobin 6.6 mmol/l (8.1 to 
10.7), platelet count 82 x 109/l (120 to 350 x 109/l), CRP 118 
mg/l (<5), total bilirubin 22 μmol/l (<10), direct bilirubin 7 
μmol/l (<5), alkaline phosphatase 142 U/l (<120), aspartate 
aminotransferase 46 U/l (<40), alanine aminotransferase 
28 U/l (<45), lactate dehydrogenase 378 U/l (<450) and 
gamma glutamyltransferase 76 U/l (<50). 
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An intra-abdominal focus of the infection was suspected 
and treatment with piperacilline and tazobactam was 
initiated. Blood cultures showed Staphylococcus aureus, 
Lactobacillus spp, anaerobe gram negative rods, viridans 
group Streptococci and Fusobacterium nucleatum. 
This suggested an origin of infection in the upper 
gastro intestinal tract. Urine cultures were negative. 
Serological tests for H. pylori taken before, appeared to be 
positive.
A CT scan still showed a deep duodenal ulcer with a close 
relation to the hepatic portal vein (figure 1A). The gas formation 
in the liver was at first interpreted as air in the biliary tract, 
which could be related to the hepatectomy. Signs of portal 
vein thrombosis were not seen. The patient recovered, his 
temperature normalised and after one week intravenous 
antimicrobial therapy was stopped. The patient continued oral 
antibiotic therapy with clarithromycin for H. pylori eradication 
and for treatment of Staphlycoccus aureus, although for the last 
indication clarithromycin was not the first choice. However, 
within 24 hours the fever and chills recurred. Treatment with 
piperacilline/tazobactam was resumed. 
A FDG-PET scan was performed and showed an increased 
FDG uptake at the liver hilus. Evaluation by CT scan was 
repeated, which now showed a thrombus in the portal 
vein (figure 1B). With this combination, the high FDG 
uptake at the liver hilus and the thrombus in the portal 
vein, the diagnosis of pylephlebitis was made. After six 
weeks of antimicrobial treatment (two weeks piperacilline/
tazobactam intravenously and four weeks amoxicillin/
clavulanic acid orally) the patient made a full recovery. 
Anticoagulant therapy was not administered due to the 
risk of fatal bleeding from his recent duodenal ulcer. After 
antimicrobial treatment chemotherapy was continued. 
Nevertheless, the patient developed progression of the 
metastatic colonic carcinoma and died a few months later.
d i s C U s s i o N
Pylephlebitis is a complication of intra-abdominal infection, 
most commonly caused by diverticulitis or appendicitis. 
Other causes have been described including cholangitis, 
pancreatitis and inflammatory bowel disease. In some of 
the patients, an underlying cause is not found.4,5 Portal 
vein thrombosis due to a duodenal ulcer has been reported 
once before.3 In our patient pylephlebitis may have been 
related to the duodenal ulcer, since the micro-organisms 
that were cultured indicated a source of infection in the 
upper gastrointestinal tract and no other underlying cause 
was found. There were no signs of local recurrence of the 
colon carcinoma neither on CT scan nor on FDG-PET that 
may cause this pylephlebitis.
Recently, it has been suggested that duodenal ulcers may 
be involved in the pathogenesis of bevacizumab-related 
bowel perforations,6 although in our patient H. pylori 
infection may also have contributed to the development of 
the duodenal ulcer.
The diagnosis of pylephlebitis is frequently delayed due 
to the nonspecific clinical signs. Symptoms with which 
patients can present are fever, chills and abdominal pain 
often without jaundice. Leucocytosis is a common finding 
and bacteraemia has been reported in most patients 
(50 to 80%).4 The infection is, as in our patient, usually 
polymicrobial. 
The demonstration of portal vein thrombosis in a febrile 
patient with bacteraemia is indicative for the diagnosis 
pylephlebitis.1,2 Imaging techniques such as CT scan, 
ultrasonography, magnetic resonance imaging (MRI) 
and angiography are all considered appropriate to detect 
thrombosis of the portal vein. However, as demonstrated 
figure 1A. CT abdomen with duodenal ulcer (small 
arrow) closely related to the portal vein (large arrow) 
and gas formation in the portal veins (*)
figure 1B. CT abdomen with portal vein thrombosis 
(arrow)
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in our patient, thrombosis may not always be visualised 
on CT scan3 and this may lead to a delay in diagnosis and 
treatment. The finding of gas formation in the portal 
vein has also been implicated in pylephlebitis, but the 
diagnosis of pylephlebitis is not proven by this.7 Another 
helpful imaging technique to diagnose pylephlebitis is 
the FDG-PET.8 Sensitivity and specificity of FDG-PET 
varies in different studies. A small study in diagnosing 
septic thrombophlebitis in patients with haematological 
malignancy showed a sensitivity and specificity of 100%. 
In a few cases diagnosis was made with FDG-PET even 
when thrombosis could not be visualised with duplex scan 
or venography.9 In other studies concerning FDG-PET 
investigation in patients with fever of unknown origin, 
sensitivity and specificity of FDG-PET are lower.10,11
In our patient there was an increased FDG activity near 
the liver hilus. In combination with the CT scan results, 
both the gas formation in the beginning and the thrombus 
in the portal vein finally confirmed the diagnosis of 
pylephlebitis. Prolonged administration of broad-spectrum 
antibiotics and eradication of the underlying cause are the 
most important in treatment of pylephlebitis. The optimal 
duration of antibiotic therapy varies in the literature from 
four to six weeks.1,4 The role of anticoagulation therapy 
remains controversial. Limited data suggest a benefit for 
patients with hypercoagulable state or mesenteric vein 
involvement.5 Other studies have noted no benefit from 
anticoagulation.4 In a review Falagas et al. suggest that 
early administration of heparin in the management of 
septic thrombophlebitis might be useful and seems to be 
safe regarding the low complication rates, but the authors 
also stated that there are too few data to make a definite 
conclusion about the effectiveness and toxicity of heparin 
in patients with septic thrombophlebitis.12 Treatment with 
thrombolytic therapy in pylephlebitis has been described 
in a few case reports but there is no conclusive evidence 
of efficacy.2 Although in our patient a hypercoagulable 
state due to the advanced cancer may have contributed 
to the development of pylephlebitis, we did not apply 
anticoagulation therapy because of its dubious role in the 
treatment of pylephlebitis and the high risk of serious 
bleeding due to the duodenal ulcer. Although the incidence 
of pylephlebitis has decreased upon the availability of 
antibiotic drugs, it still caries a high mortality rate of 
11 to 32%.4,5 Pylephlebitis may be complicated by severe 
therapy-resistant sepsis, which is responsible for the high 
mortality rates.4 Other complications include hepatic 
abscess formation, and less commonly progression 
of the thrombus into the mesenteric vein and portal 
hypertension.3-5 In conclusion, pylephlebitis is a rare but 
serious condition, which may be difficult to diagnose even 
with imaging techniques such as CT scan. It should be 
considered in patients with sepsis due to gut-associated 
organisms without a clear source of infection. FDG-PET 
seems to be a useful additional method for diagnosing 
septic thrombophlebitis.
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